

Simona Pagliuca

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9425718/publications.pdf>

Version: 2024-02-01

57
papers

428
citations

933447

10
h-index

839539

18
g-index

58
all docs

58
docs citations

58
times ranked

638
citing authors

#	ARTICLE	IF	CITATIONS
1	Allogeneic reactivity-mediated endothelial cell complications after HSCT: a plea for consensual definitions. <i>Blood Advances</i> , 2019, 3, 2424-2435.	5.2	66
2	Vacuolization of hematopoietic precursors: an enigma with multiple etiologies. <i>Blood</i> , 2021, 137, 3685-3689.	1.4	50
3	A Therapeutic Strategy for Preferential Targeting of <i>TET2</i> -Mutant and <i>TET</i> Dioxygenase-Deficient Cells in Myeloid Neoplasms. <i>Blood Cancer Discovery</i> , 2021, 2, 146-161.	5.0	36
4	The similarity of class II HLA genotypes defines patterns of autoreactivity in idiopathic bone marrow failure disorders. <i>Blood</i> , 2021, 138, 2781-2798.	1.4	27
5	Long-Term Outcomes of Cord Blood Transplantation from an HLA-Identical Sibling for Patients with Bone Marrow Failure Syndromes: A Report From Eurocord, Cord Blood Committee and Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1939-1948.	2.0	19
6	Evaluation of Graft Versus Host Disease and Relapse Free Survival As Novel Endpoint in Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Joint Naples-Paris Study. <i>Blood</i> , 2016, 128, 2285-2285.	1.4	15
7	Eltrombopag inhibits <i>TET</i> dioxygenase to contribute to hematopoietic stem cell expansion in aplastic anemia. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	15
8	Elastography improves accuracy of early hepato-biliary complications diagnosis after allogeneic stem cell transplantation. <i>Haematologica</i> , 2021, 106, 2374-2383.	3.5	14
9	Molecular Targeted Therapy in Myelodysplastic Syndromes: New Options for Tailored Treatments. <i>Cancers</i> , 2021, 13, 784.	3.7	14
10	Deciphering the Therapeutic Resistance in Acute Myeloid Leukemia. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8505.	4.1	12
11	Clinical and basic implications of dynamic T cell receptor clonotyping in hematopoietic cell transplantation. <i>JCI Insight</i> , 2021, 6, .	5.0	12
12	<i>TET2</i> mutations as a part of DNA dioxygenase deficiency in myelodysplastic syndromes. <i>Blood Advances</i> , 2022, 6, 100-107.	5.2	12
13	Novel invariant features of Good syndrome. <i>Leukemia</i> , 2021, 35, 1792-1796.	7.2	11
14	Is nature truly healing itself? Spontaneous remissions in Paroxysmal Nocturnal Hemoglobinuria. <i>Blood Cancer Journal</i> , 2021, 11, 187.	6.2	11
15	Human-Derived α 1-Antitrypsin is Still Efficacious in Heavily Pretreated Patients with Steroid-Resistant Gastrointestinal Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1620-1626.	2.0	10
16	Implication of <i>PIGA</i> genotype on erythrocytes phenotype in Paroxysmal Nocturnal Hemoglobinuria. <i>Leukemia</i> , 2021, 35, 2431-2434.	7.2	10
17	Personalized Risk Schemes and Machine Learning to Empower Genomic Prognostication Models in Myelodysplastic Syndromes. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2802.	4.1	10
18	Epstein-Barr Virus-Associated Post-Transplantation Lymphoproliferative Disease in Patients Who Received Anti-CD20 after Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2490-2500.	2.0	9

#	ARTICLE	IF	CITATIONS
19	A monocentric study of steroid-refractory acute graft-versus-host disease treatment with tacrolimus and mTOR inhibitor. <i>Bone Marrow Transplantation</i> , 2020, 55, 86-92.	2.4	9
20	Long-term outcomes and risk factor analysis of steroid-refractory graft versus host disease after hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 38-49.	2.4	9
21	Cord blood transplantation for bone marrow failure syndromes: state of art. <i>Stem Cell Investigation</i> , 2019, 6, 39-39.	3.0	8
22	Frequency and perturbations of various peripheral blood cell populations before and after eculizumab treatment in paroxysmal nocturnal hemoglobinuria. <i>Blood Cells, Molecules, and Diseases</i> , 2021, 87, 102528.	1.4	8
23	The Interactome between Metabolism and Gene Mutations in Myeloid Malignancies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3135.	4.1	5
24	Alternative Splicing in Myeloid Malignancies. <i>Biomedicines</i> , 2021, 9, 1844.	3.2	5
25	A non- cytotoxic regimen of decitabine to treat refractory T cell large granular lymphocytic leukemia. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e04533.	0.5	3
26	Epigenetic Enzyme Mutations in Myeloid Malignancies Are Selected By Chromatin-Remodeling Requirements That Vary By Lineage- and Maturation-Stage. <i>Blood</i> , 2021, 138, 1148-1148.	1.4	3
27	A study of Telomerase Reverse Transcriptase rare variants in myeloid neoplasia. <i>Hematological Oncology</i> , 2022, , .	1.7	3
28	Success of haploidentical hematopoietic stem cells transplantation in the treatment of graft failure. <i>Annals of Hematology</i> , 2016, 95, 353-354.	1.8	2
29	Clonal trajectories and cellular dynamics of myeloid neoplasms with SF3B1 mutations. <i>Leukemia</i> , 2021, 35, 3324-3328.	7.2	2
30	Monoclonal IgM gammopathy in adult acquired pure red cell aplasia: culprit or innocent bystander?. <i>Blood Cells, Molecules, and Diseases</i> , 2021, 91, 102595.	1.4	2
31	Current Opinions on the Clinical Utility of Ravulizumab for the Treatment of Paroxysmal Nocturnal Hemoglobinuria. <i>Therapeutics and Clinical Risk Management</i> , 2021, Volume 17, 1343-1351.	2.0	2
32	Rare germline alterations of myeloperoxidase predispose to myeloid neoplasms. <i>Leukemia</i> , 2022, 36, 2086-2096.	7.2	2
33	Aplastic Anemia & MDS International Foundation (AA&MDSIF): Bone Marrow Failure Disease Scientific Symposium 2018. <i>Leukemia Research</i> , 2019, 80, 19-25.	0.8	1
34	Thrombocytapheresis and sequential chemotherapy for extreme symptomatic thrombocytosis secondary to myelofibrosis: a case report. <i>Annals of Hematology</i> , 2020, 99, 897-898.	1.8	1
35	Friend or foe? The case of Wilms' Tumor 1 (WT1) mutations in acute myeloid leukemia. <i>Blood Cells, Molecules, and Diseases</i> , 2021, 88, 102549.	1.4	1
36	The Clonal Trajectories of SF3B1 Mutations in Myeloid Neoplasia. <i>Blood</i> , 2020, 136, 8-8.	1.4	1

#	ARTICLE	IF	CITATIONS
37	The Genomic Landscape of Myeloid Neoplasms Evolved from AA/PNH. <i>Blood</i> , 2020, 136, 2-2.	1.4	1
38	Impact of Pathogenic Germ Line Variants in Adults with Acquired Bone Marrow Failure Syndromes Vs. Myeloid Neoplasia. <i>Blood</i> , 2020, 136, 1-1.	1.4	1
39	Immunogenetic, Molecular and Clinical Determinants of Clonal Evolution in Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria. <i>Blood</i> , 2021, 138, 602-602.	1.4	1
40	A Novel Machine Learning-Derived Molecular Classification Scheme with Prognostic Significance. <i>Blood</i> , 2021, 138, 3666-3666.	1.4	1
41	Molecular characterization of the histone acetyltransferase CREBBP/EP300 genes in myeloid neoplasia. <i>Leukemia</i> , 2021, , .	7.2	1
42	Spectrum of Molecular Modes of Immune Escape in Idiopathic Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria. <i>Blood</i> , 2021, 138, 603-603.	1.4	1
43	Transcriptomic Profile Identifies Early Signatures of Immunoediting and a Potential Role for VISTA As a Molecular Target in Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 4467-4467.	1.4	1
44	The Genomic Landscape of Wilms' Tumor 1 (WT1) Mutant Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 28-28.	1.4	1
45	Point-of-care ultrasound with handheld devices in hematology: a monocentric single-stage phase II study. <i>Leukemia and Lymphoma</i> , 2021, 62, 1379-1385.	1.3	0
46	Is Nature Truly Healing Itself? Spontaneous Remissions and Clonal Replacement in Paroxysmal Nocturnal Hemoglobinuria. <i>Blood</i> , 2021, 138, 4303-4303.	1.4	0
47	Molecular Signatures of Immune Pressure and Immune Escape in Hematological Malignancies. <i>Blood</i> , 2021, 138, 1093-1093.	1.4	0
48	Type of TP53 Mutations Affects Subclonal Configuration and Selection Pressure for Acquisition of Additional Hits in Contralateral Alleles. <i>Blood</i> , 2020, 136, 25-25.	1.4	0
49	Immunogenomics of Paroxysmal Nocturnal Hemoglobinuria: A Model of Immune Escape. <i>Blood</i> , 2020, 136, 21-22.	1.4	0
50	Impact of HLA Evolutionary Divergence on Clinical Features of Patients with Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria. <i>Blood</i> , 2020, 136, 2-3.	1.4	0
51	Inhibition of Critical DNA Dioxygenase Activity in IDH1/2 Mutant Myeloid Neoplasms. <i>Blood</i> , 2020, 136, 28-28.	1.4	0
52	Implication of Piga Genotype on Clinical Features of PNH. <i>Blood</i> , 2020, 136, 34-35.	1.4	0
53	Double Genetic Hits and Subclonal Mosaicism in the Ras Signaling Pathway in Myeloid Neoplasia. <i>Blood</i> , 2020, 136, 34-35.	1.4	0
54	Immunogenomics of Aplastic Anemia: The Role of HLA Somatic Mutations and the HLA Evolutionary Divergence. <i>Blood</i> , 2020, 136, 20-21.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Rare Germline Alterations of Myeloperoxidase Predispose to Myeloid Neoplasms and Are Associated with Increased Circulating Burden of Microbial DNA. <i>Blood</i> , 2020, 136, 2-3.	1.4	0
56	Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: From Recapitulation/Acquisition of Leukemogenic Hits to Immune Escape Due to Somatic Class I/ II HLA Mutations. <i>Blood</i> , 2020, 136, 21-21.	1.4	0
57	Comparative Genomic Analysis of Adolescents and Young Adults Versus Elderly with Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 18-18.	1.4	0